GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Ending Cash Position

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Ending Cash Position : ¥1,111 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co Ending Cash Position?

Shijiazhuang Yiling Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥1,111 Mil.

Shijiazhuang Yiling Pharmaceutical Co's quarterly Ending Cash Position declined from Sep. 2023 (¥992 Mil) to Dec. 2023 (¥847 Mil) but then increased from Dec. 2023 (¥847 Mil) to Mar. 2024 (¥1,111 Mil).

Shijiazhuang Yiling Pharmaceutical Co's annual Ending Cash Position increased from Dec. 2021 (¥953 Mil) to Dec. 2022 (¥1,811 Mil) but then declined from Dec. 2022 (¥1,811 Mil) to Dec. 2023 (¥847 Mil).

Shijiazhuang Yiling Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co Ending Cash Position Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 713.41 1,234.17 953.48 1,810.66 846.63

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 940.32 1,653.23 991.60 846.63 1,110.97

Shijiazhuang Yiling Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shijiazhuang Yiling Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1810.664+-964.03
=847

Shijiazhuang Yiling Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=846.634+264.337
=1,111

Shijiazhuang Yiling Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Ending Cash Position
Comparable Companies
SZSE:300142 SHSE:600079 SHSE:688506 SZSE:300601 SZSE:000999 SZSE:000423 SHSE:600332 SZSE:000513 SHSE:688276 SZSE:002262 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN
Website
http://www.yiling.cn/
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.
Executives
Zhang Qiu Lian Directors, executives
Han Yue Zhi Executives
Zhao Shao Hua Executives
Wang Wei Executives
Gao Xue Dong Supervisors
Wu Yi Ling Director
Gao Xiu Qiang Executives
Wu Xiang Jun Directors, executives
Guo Shuang Geng Director
Wang Hua Securities Affairs Representative
Dai Feng Xiang Directors, executives
Liu Gen Wu Supervisors
Wang Wei Ping Directors, executives
Xu Wei Dong Director
Wu Rui Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines